There are an estimated 1.5 billion people on earth living with chronic pain. Current treatments are, to put it diplomatically, not good enough. Gabapentin (one of the most widely prescribed drugs for neuropathic pain) fails for somewhere between 30 and 50% of patients. Opioids carry addiction risk that has produced its own epidemic. And most analgesics require daily dosing, lose efficacy through tolerance, and do nothing about the underlying network dysfunction that keeps chronic pain chronic.
This is the problem a team of researchers at the University of Reading, in collaboration with Compass Pathways, set out to address. Their paper, juts published in Communications Biology, suggests that psilocybin offers a unique solution.
Let me walk you through it.
The Setup
The researchers used the spared nerve injury (SNI) model – the gold standard in preclinical neuropathic pain research. It involves surgically damaging specific branches of the sciatic nerve while leaving others intact, producing a persistent state of mechanical hypersensitivity (pain from stimuli that shouldn’t be painful) that closely mirrors conditions like post-surgical nerve damage, diabetic neuropathy, and trauma-induced neuropathy in humans.
Once the mice had developed full mechanical hypersensitivity, they received a single injection of psilocybin (either 1 mg/kg or 0.3 mg/kg) and were then monitored across a range of behavioural tests.
Both doses worked.
At the higher dose, mechanical hypersensitivity (pain response to physical touch or pressure) was significantly reduced in both male and female mice. In males, the effect lasted up to 28 days post-injection.
At the lower dose (0.3 mg/kg), the effect was smaller in magnitude but still lasted 28 days. When that lower dose was repeated weekly for three weeks, the analgesia was amplified substantially, reaching a maximum possible effect of 62.6% and persisting across the entire monitoring period.
None of this impaired locomotor function, meaning the mice weren’t sedated or incapacitated. They were just… in less pain.
The Mechanism: 5-HT2A Receptors and the Network Reset
The researchers wanted to know whether the analgesic effect required the 5-HT2A receptor, which is the primary serotonin receptor through which psilocybin produces its psychedelic effects. So they pre-treated mice with volinanserin, a selective 5-HT2A antagonist, before administering psilocybin.
Volinanserin blocked the head-twitch response (the rodent behavioural proxy for psychedelic effects) and substantially reduced psilocybin’s anti-nociceptive effect. Not completely though, which is interesting in itself, suggesting that other mechanisms (BDNF signalling, 5-HT1A agonism, spinal cord pathways) may also contribute. But the primary driver of pain relief appears to be 5-HT2A receptor activation.
This connects to what we know about psilocybin’s broader mechanism. 5-HT2A activation in the prefrontal cortex drives the rapid growth of dendritic spines. It normalises activity in the anterior cingulate cortex (ACC), a region that sits at the crossroads of sensory pain processing and emotional suffering. And critically, it appears to reset maladaptive functional connectivity patterns – the kind that, in chronic pain, have become locked in a self-reinforcing loop.
The authors describe this as psilocybin acting as a “network-restructuring agent.” That framing suggests psilocybin isn’t simply suppressing pain signals the way an opioid does. It’s actually remodelling the infrastructure that generates and sustains chronic pain.
One especially notable finding supports this interpretation. When the researchers gave psilocybin 30 days before the nerve injury surgery, it had no preventive effect. The mechanical hypersensitivity developed on the same timeline as the control group.
Psilocybin, in other words, doesn’t prevent the pain network from forming, but it can dismantle one that’s already established. Suggesting it needs maladaptive connectivity to work on.
The Most Important Finding
The researchers ran two experiments examining how psilocybin interacted with gabapentin.
In the first, gabapentin was administered when both drugs were pharmacologically active simultaneously. The combination produced significantly greater and longer-lasting pain relief than gabapentin alone. An additive, possibly synergistic effect.
That’s interesting. But the second experiment is more extraordinary.
Gabapentin was administered 55 days after the SNI surgery, at a timepoint when psilocybin’s own direct analgesic effect was completely undetectable because it had been given at day 12.
In the saline-treated mice, gabapentin produced its usual modest, short-lived effect. In the mice that had received psilocybin 43 days earlier, gabapentin produced a dramatic, sustained anti-nociceptive (pain-blocking) effect lasting from 2 to 96 hours.
So a single dose of psilocybin, given six weeks prior, transformed the responsiveness of an existing painkiller at a timepoint when psilocybin itself was producing no measurable pain relief. So the psilocybin was gone, but the change in the network remained.
This is what the authors mean by “pain-network primer.” Psilocybin appears to restructure the neural architecture of pain processing in a way that persists long after the pharmacological window has closed. And that restructuring makes established analgesics work more effectively.
The implications are significant. The 30-50% of neuropathic pain patients who don’t respond adequately to gabapentin monotherapy may not need a new drug. They may need their existing drug administered after being primed to respond to it with psilocybin.
What This Connects To
If you’ve been following the science here at The Spore Report, this finding slots into a pattern we’ve been tracing for a while.
Psilocybin’s most consistent mechanism appears to be network-level reorganisation. The REBUS model (Relaxed Beliefs Under Psychedelics) frames this as a flattening of the brain’s prediction error hierarchy, allowing top-down beliefs to be updated from the bottom up. The Daws et al. (2022) brain integration study showed increased global connectivity after psilocybin therapy for depression. The dendritic spine work from Shao et al. (2021) gave us a structural correlate for those network changes.
What this new study adds is a temporal dimension to that picture. The network changes induced by psilocybin create a biological environment that persists for weeks and enhances the efficacy of subsequent interventions.
That’s a completely different model of how a drug can work. A molecule that alters the terrain on which other molecules operate.
The authors raise BDNF as a candidate mechanism. Brain-derived neurotrophic factor is the the signalling molecule that drives structural neuroplasticity. Psilocybin promotes BDNF release in the frontal cortex and the dorsal horn of the spinal cord. BDNF in the rostral ventromedial medulla has already been shown to potentiate morphine efficacy at otherwise sub-therapeutic doses. Whether similar BDNF-mediated mechanisms explain the gabapentin enhancement observed here is, the authors note, a question for future investigation.
It’s one I’ll be watching closely.
The Caveats
This is a preclinical study on mice. The SNI model is excellent, but it cannot fully capture the subjective and psychological dimensions of chronic pain in humans.
The study also involved relatively small group sizes (5-12 per group), consistent with exploratory preclinical work but not sufficient to draw confident conclusions about dose-response relationships, sex differences, or the durability of the gabapentin potentiation effect across longer timescales.
One counterpoint in the literature is worth acknowledging: a 2026 study found no evidence of analgesic effect from psilocybin in three mouse pain models. The methodological differences between these studies matter enormously and are not yet fully resolved. The field is still early.
What this paper does establish is proof-of-concept for a mechanism that, if it translates to humans, would represent a novel approach to one of medicine’s most stubborn problems.
Beyond Pain
I want to end with a slightly bigger frame.
Chronic pain and treatment-resistant depression share significant overlap neurologically, psychologically, and epidemiologically speaking. People with chronic pain are significantly more likely to develop depression and anxiety. The two conditions co-evolve, share neural circuits, and frequently don’t respond to the same interventions that work in more uncomplicated presentations.
If psilocybin can prime the pain network for enhanced analgesic responsiveness, it raises the question if can it do the same for the emotional and psychological dimensions of chronic pain? Can it prime the system for better therapeutic uptake from CBT, acceptance-based approaches, or the kind of integration work we focus on in the AfterGrow framework?
The answer isn’t in this paper, but it’s interesting to consider.
Study reference: Askey T, Allen-Ross D, Luzyanin D, et al. Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. Communications Biology (2026). https://doi.org/10.1038/s42003-026-10065-7
